Impact of tDCS on Cerebral Autoregulation

Migraine With Aura Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01865604
• Other study ID #: tDCS_cVMR
• Status: Completed
• Phase: N/A
• First received: December 18, 2012
• Last updated: March 15, 2016
• Start date: April 2012
• Est. completion date: March 2014

Study information

• Verified date: March 2016
• Source: Charite University, Berlin, Germany
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to investigate whether there is a polarity-specific influence of tDCS on cerebral vasomotor reactivity monitored by transcranial doppler sonography.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: March 2014
• Est. primary completion date: March 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. severe cerebral Microangiopathy

2. NOTCH3 carrier

3. Migraine with aura (IHS Classification ICHD-II)

4. Stenosis >80%, ECST-Criteria

Exclusion Criteria:

• seizure disorder

• history of severe alcohol or drug abuse, psychiatric illness like severe depression, poor motivational capacity

• dementia

(1+2) history of stroke in past 3 months (3) migraine prophylaxis (4) contralateral stenosis >50%,

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• CADASIL
• Cerebral Microangiopathy
• Cerebral Small Vessel Diseases
• ICA Stenosis
• Migraine With Aura

Intervention

Device:
• Anodal tDCS

• Cathodal tDCS

• sham tDCS

Locations

Country	Name	City	State
Germany	Department of Neurology, Charité Universitätsmedizin Berlin	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cerebral vasomotor reactivity assessed by transcranial Dopplersonography	comparing cerebral vasomotor reactivity at baseline and after anodal/cathodal/sham stimulation	on 3 days within 12 weeks	No